Chemistry:EcPLA

From HandWiki

EcPLA, also known as N-ethyl-N-cyclopropyllysergamide or as lysergic acid ethylcyclopropylamide (LAEcP), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2][3] It is an isomer of LSZ and is closely related to other amide-substituted lysergamides like MiPLA.[2][1][4][3] The drug has been encountered as a novel designer drug.[3]

Use and effects

EcPLA produces psychedelic effects in humans.[3]

Interactions

Pharmacology

Pharmacodynamics

EcPLA has been found to interact with serotonin receptors and dopamine receptors, among other targets. It is a high potency agonist of the serotonin receptors, with its highest binding affinities at the 5-HT1A (Ki = 3.2 nM), 5-HT2B (Ki = 5.3 nM), and 5-HT5A (Ki = 8.6 nM) subtypes. Its 5-HT2A affinity is equivalent to that of LSD, while the affinity to 5-HT2C receptors is 3 times lower than LSD. It shares much of its binding profile with LSD, but does not bind to β1 or β2 adrenergic receptors as LSD does.[2]

The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It has about 40% of the potency of LSD in this regard.[2]

Pharmacokinetics

The in-vitro metabolism of EcPLA has been studied.[5]

Chemistry

Analogues

Analogues of EcPLA include MiPLA, LAMPA (MPLA), EPLA, EiPLA, ETFELA, and LSZ, among others.[4][2][1]

History

EcPLA was first described in the scientific literature by a team that included Adam Halberstadt, Alexander Stratford, Jason Wallach, and David E. Nichols in 2019.[2] It was developed by Lizard Labs. The drug was encountered online as a novel designer drug in around 2020 and became more widely available in early 2022.[3]

See also

References

  1. ↑ 1.0 1.1 1.2 "Analytical profile of N-ethyl-N-cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4-dimethylazetidide (LSZ)" (in en). Drug Testing and Analysis 12 (10): 1514–1521. 2020. doi:10.1002/dta.2911. ISSN 1942-7611. PMID 32803833. 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)". Psychopharmacology 236 (2): 799–808. February 2019. doi:10.1007/s00213-018-5117-z. PMID 30298278. 
  3. ↑ 3.0 3.1 3.2 3.3 3.4 "ECPLA" (in ru). https://aipsin.com/newsubstance/831/. 
  4. ↑ 4.0 4.1 "A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies". Analyst 150 (2): 290–308. January 2025. doi:10.1039/d4an01361a. PMID 39636448. 
  5. ↑ "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures". Analytical and Bioanalytical Chemistry 411 (19): 4751–4763. July 2019. doi:10.1007/s00216-018-1558-9. PMID 30617391. http://researchonline.ljmu.ac.uk/id/eprint/9841/13/ABC-01967-2018_02_accepted.pdf. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:EcPLA&oldid=4309557"